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Primary prostate cancer almost always has a luminal
phenotype. However, little is known about the stem/
progenitor properties of transformed cells within tu-
mors. Using the aggressive Pten/Tp53-null mouse
model of prostate cancer, we show that two classes
of luminal progenitors exist within a tumor. Not
only did tumors contain previously described multi-
potent progenitors, but also a major population of
committed luminal progenitors. Luminal cells, sorted
directly from tumors or grown as organoids, initiated
tumors of adenocarcinoma or multilineage histologi-
cal phenotypes, which is consistent with luminal and
multipotent differentiation potentials, respectively.
Moreover, using organoids we show that the ability
of luminal-committed progenitors to self-renew is a
tumor-specific property, absent in benign luminal
cells. Finally, a significant fraction of luminal progen-
itors survived in vivo castration. In all, these data
reveal two luminal tumor populations with different
stem/progenitor cell capacities, providing insight
into prostate cancer cells that initiate tumors and
can influence treatment response.
INTRODUCTION
Epithelial tissues have remarkable capacities to repair damage
and maintain homeostasis as a result of cell divisions mediated
by stem cells located within special microenvironments (Morri-
son and Spradling, 2008). Particularly relevant to tumorigenesis
are a variety of recent findings showing that the differentiation
pathway of epithelial cells can be plastic. Even committed
normal epithelial cells can dedifferentiate to a stem-like state in
certain nonhomeostatic conditions of severe injury (summarizedCell Repin Blanpain and Fuchs, 2014). This has implications for the
‘‘memory’’ of transformed epithelium relative to re-expression
of stem cell lineage properties. An interesting example comes
from mammary epithelium. There is evidence for multipotent
stem cells in the developing and adult mammary gland (Rios
et al., 2014; Van Keymeulen et al., 2011). Following inactivation
of BRCA1 in luminal-committed mammary cells, progressive
tumors demonstrate reacquisition of multipotent stem cell prop-
erties such as combined basal and luminal marker expression
(Molyneux et al., 2010). Similarly, for prostate cancer, there are
questions about how the cell of origin and/or characteristics of
cancer stem/progenitor cell populations may affect various
important properties including treatment resistance (Shibata
and Shen, 2013; Wang and Shen, 2011; Zong and Goldstein,
2013).
Prostate glands are composed of an outer layer of basal cells
expressing KRT5, KRT14, and TP63, an inner layer of secretory,
luminal cells expressing KRT8, KRT18, and AR, and rare SYP
and CHGA positive neuroendocrine cells (Shen and Abate-
Shen, 2010). TP63 is a marker of prostate basal epithelial and
stem cells and is required for prostate development (Pignon
et al., 2013). Lineage tracing studies based upon cytokeratin
drivers have established a number of principles for stem cell hi-
erarchies in the developing and adult prostate (Choi et al., 2012;
Ousset et al., 2012; Wang et al., 2013). The majority of regener-
ative adult stem cells appear to be unipotent (Choi et al., 2012;
Wang et al., 2013). In addition, studies using other lineage tracing
schemes have described minor populations of multipotent pro-
genitor cells that have not been captured with KRT-specific
drivers. Using an inducible NKX3.1-specific CRE driver, a rare
(0.7%) population of bipotential luminal cells in the castrate pros-
tate (CARNs) has been described (Wang et al., 2009). In addition,
the existence of KRT5neg, KRT14neg,TP63+ cells has been
observed, as well as the ability of TP63 lineage marked cells to
generate luminal epithelial cells in the adult (Lee et al., 2014).
Therefore, there are hints of multipotent stem/progenitor cells
in the intact (non-castrate) prostate, as well.orts 13, 2147–2158, December 15, 2015 ª2015 The Authors 2147
Prostate cancer is almost always luminal in phenotype (Hum-
phrey, 2012). Appropriate CRE drivers have been used to
analyze the consequences of Pten deletion in basal, luminal,
and castration-resistant NKX3.1-expressing (CARN) cells. Pten
deletion in luminal cells and CARNs gave rise to prostatic intra-
epithelial neoplasia (PIN)/early cancer and microinvasive adeno-
carcinoma (Choi et al., 2012; Wang et al., 2009). In addition, Pten
loss in basal cells led to PIN/early cancer associated with basal
to luminal differentiation (Choi et al., 2012; Wang et al., 2013).
These studies established that CARNs aswell as broadly defined
basal and luminal cells can serve as experimental cells of origin
for prostate cancer and strongly suggest that Pten deletion pro-
motes prostatic epithelial transformation in the context of luminal
lineage commitment.
Tumor-initiating cells (TICs), defined by clonal tumor initiation
from transplanted cells, have not been analyzed in primary pros-
tate cancers, partly due to the poor transplantation ability of sin-
gle-cell suspensions of human prostate cancers and low-grade
mouse tumors (Toivanen et al., 2011). This may be due to the
fragility of fractionated prostate tumor cells, to a high percentage
of indolent cells in primary tumors, to a strict requirement for the
proper microenvironment, or to other unknown reasons. In
Probasin-CRE (PB-CRE) driven Pten-null tumors, fractionation
and co-transplantation with embryonic urogenital mesenchyme
(UGM) of bulk CD49fhi basal cells but not CD49flo luminal cells
led to the development of histologically abnormal glands, sug-
gesting that transformed cells initiating tumorigenesis exist in
the basal cell fraction (Mulholland et al., 2009). However, to
date, definitive evidence for clonal tumor-initiating stem cells in
primary prostate cancer is lacking (Wang and Shen, 2011).
Prior ex vivo prostate stem/progenitor studies have been con-
strained by culture conditions that promote basal but not luminal
stem/progenitor cell growth (Xin et al., 2007). The recent devel-
opment of organoid culture methods that support long-term
propagation of luminal epithelium has extended our ability to
phenotype and manipulate prostate stem/progenitor cells
(Chua et al., 2014; Karthaus et al., 2014). Organoid cultures
have revealed the presence of multipotent stem/progenitor cells,
capable of reconstituting prostate glands in vivo following UGM
recombination assays, within the luminal fraction of mouse and
human prostates (Chua et al., 2014; Karthaus et al., 2014). In
addition, populations of genetically modified, mouse multiline-
age organoids gave rise to histologically abnormal, hyperproli-
ferative glands in recombination assays, suggesting an ability
to serve as cells of origin for prostate cancer (Chua et al.,
2014; Karthaus et al., 2014). There have been technical limita-
tions to growing primary human prostate cancer in organoid
cultures (Karthaus et al., 2014), and, therefore, the expression
of the multilineage stem/progenitor phenotype in primary human
prostate cancer has yet to be determined.
Organoid cultures demonstrate a luminal stem/progenitor cell
with multilineage potential, although the existence of such stem/
progenitor cells has not been observed in adult mouse tissues
with luminal KRT driver-dependent tracing schemes, suggesting
important questions. First, is multipotentiality conditionally
induced in culture or do organoid-defined multipotent luminal
cells reflect their in vivo differentiation pathway? Second, is
there a definable relationship between multipotent and TP63neg2148 Cell Reports 13, 2147–2158, December 15, 2015 ª2015 The Auluminal cells, the latter of which are characteristic of prostate
cancer?
Here, we use the aggressive Pten/Tp53-null model of mouse
prostate cancer in combination with organoid cultures and clonal
TIC assays to characterize luminal stem/progenitor cell popula-
tions and their relationship to tumorigenesis. PTEN and TP53 are
two of the most frequently deleted or mutated genes in primary
prostate cancers, which often are co-selected (Boutros et al.,
2015; Taylor et al., 2010). In addition, TP53 is themost selectively
enriched altered gene in metastatic castration-resistant prostate
cancer (Robinson et al., 2015), and therefore, insights into the
functional consequences of Tp53 inactivation in prostate epithe-
lium will inform the development of hypotheses related to mech-
anism of metastasis and acquired resistance. Compared to
Pten-null prostate cancer, the Pten/Tp53-null prostate cancer
model produces significantly faster growing tumors and early
mortality (Chen et al., 2005; Martin et al., 2011). Also, Pten/
Tp53 tumors are more heterogeneous, being composed primar-
ily of adenocarcinoma but also displaying adenosquamous as
well as sarcomatoid differentiation at late stages of disease
(Martin et al., 2011), suggesting that the PB-CRE4 driver is
active in stem cells and/or that Tp53 deletion leads to a high level
of differentiation plasticity. Here, we present evidence delin-
eating stem/progenitor phenotypes and their relationship to
pathogenesis. We demonstrate the amplification of transformed,
luminal stem/progenitor cells in aggressive primary prostate
tumors, show that luminal multipotent and luminal-committed
progenitors are serial stages in lineage differentiation, and iden-
tify the autonomous tumor-initiating cells in primary prostate
tumors.
RESULTS
CD49f and Prominin-1 Fractionate EpCAM+
Pten/,Tp53/ Prostate Adenocarcinoma Cells into
Basal and Luminal Populations
To interrogate discreet tumor subpopulations, we analyzed by
flow cytometry the expression of various epithelial lineage and/or
potential cancer stem cell markers in PB-CRE4, Ptenfl/fl Tp53fl/fl
prostate tumors. After excluding hematopoietic and endothelial
cells, flow cytometry was used to characterize combinations of
markers on EpCAM+ tumor cell suspensions. Unlike normal
prostate tissue, tumor epithelial populations were not fraction-
ated into subpopulations by either Sca-1 or CD24 surface
expression, both of which showed a continuum of relatively
strong expression (Figure S1). To separate basal and luminal
cells, respectively, EpCAM+ cells were separated into CD49fhi
and CD49fmed/lo fractions, detecting high and low ITGA6 levels
(Figure 1A; Figure S2A). Prominin-1 (PROM1), which is widely ex-
pressed on mouse luminal cells (Missol-Kolka et al., 2011), was
used to further resolve cell subpopulations. The antibody used
here is directed against a protein epitope and not against the
controversial stem cell glycosylation epitope, AC133. More
than half of the CD49fmed/lo cells labeled with PROM1 antibody
(hereafter referred to as PROM1+), whereas there was no appre-
ciable labeling of the CD49fhi basal population. Fluorescence-
activated cell sorting (FACS) was used to separate and recover
three populations from the prostate tissue: CD49fhi, PROM1+,thors
Figure 1. CD49f and PROM1 Fractionate
EpCAM+ Pten/,Tp53/ Prostate Basal
and Luminal Progenitor Populations
(A)RepresentativeFACSplot ofCD49f andPROM1
staining of primary EpCAM+ Pten/,Tp53/
prostate cells. P7 (purple), CD49fhi; P8 (orange),
PROM1+; P9 (green), CD49flo PROM1neg.
(B) qRT-PCR analysis of Itga6 and Prom1 gene
expression from the indicated cell fractions. RNA
levels were normalized to Gapdh.
(C and D) qRT-PCR analysis of lineage marker
genes in the indicated cell fractions of Pten/,
Tp53/ (C) and WT (D) prostates. The data are
reported as mean ± SEM.
(E and F) Quantification by immunofluorescent
staining of TP63+ KRT5+, KRT8+, and KRT8+/
KRT5+ cells in the indicated fractions isolated
from primary Pten/,Tp53/ (E) and WT (F)
prostate tissue. The average of three independent
experiments is shown. The data are reported as
mean ± SEM.
(G) Schematic showing that cells from Pten/,
Tp53/ prostates were fractionated and assayed
for organoid formation or were transplanted
directly into NOD/SCID mice for tumor initiation
assays. G1 organoids were harvested, dissoci-
ated, and transplanted in vivo to assess tumori-
genesis.
See also Figures S1 and S2.and CD49flo PROM1neg cells. The fractions corresponding to
CD49fhi and PROM1+ each include 5%–20% of the EpCAM+
fraction. Post-sort purity scans were performed on all three pop-
ulations, and purities of >95% were routinely achieved (Fig-
ure S2A). Similar FACS distribution profiles were observed for
wild-type (i.e., Ptenfl/fl;Tp53fl/fl;PB-CRE4neg littermates) (Fig-
ure S3) and tumor-bearing prostates.
qRT-PCR was used to confirm the differential expression of
Itga6 and Prom1 in the relevant fractions (Figure 1B) and to inter-
rogate the expression of prostate lineage markers, TP63, KRT5,
and KRT18. Importantly, for both tumor and wild-type (WT) pros-
tate, Tp63 RNA was expressed in the CD49fhi fraction but was
almost undetectable in the CD49fmed/lo cells (Figures 1C and
1D). Consistent with RNA data, nuclear TP63 immunofluores-
cence staining demonstrated a significant enrichment (>90%)
in the CD49fhi fraction and <3% in CD49fmed/lo fractions (Figures
1E and 1F). The distribution of cells expressing the definitiveCell Reports 13, 2147–2158, Debasal cell marker, TP63, indicates a
distinct separation of basal and luminal
cells.
Interestingly, an analysis of cytokeratin
expression suggests different propor-
tions of lineage subpopulations in tumor
as compared to WT for both basal and
luminal fractions. For the CD49fhi fraction,
tumor cells expressed high levels of RNA
encoding Krt5 as well as lower levels of
Krt18. Immunofluorescent co-staining of
KRT5 and KRT8 in the tumor basal frac-
tion demonstrated about 90%KRT5+8negand a small fraction of KRT5+8+ cells (Figure 1E). WT CD49fhi
cells expressed robust levels of Krt5 and Krt18. Greater than
95% of cells within the basal fraction stained strongly for
KRT5, and a significant subpopulation (30%–40%) of cells
were composed of KRT5+, KRT8+, and TP63+ co-stained cells
(Figure 1F). These data are consistent with publications
describing the presence of a substantial population of basal
KRT5++/KRT8+ cells identified by in situ immunofluorescent
staining of normal mouse (Peng et al., 2011) and human (van
Leenders et al., 2000) prostate tissue as well as in transgenic
KRT5 and KRT18 promoter reporter mice (Peng et al., 2011).
KRT staining patterns for the PROM1+ fractions from tumor
and WT demonstrated approximately 80% KRT8+ cells. Tu-
mor-derived cells also frequently expressed low levels of
KRT5, suggesting a possible intermediate or transitional pheno-
type. The CD49flo PROM1neg fractions contained mostly KRT8+
and cytokeratin negative populations.cember 15, 2015 ª2015 The Authors 2149
Figure 2. Tumor-Derived Basal and Luminal
Progenitors Are Almost All PTEN Null
(A) Comparison of first-generation organoid for-
mation from wild-type (WT), Pten/, and Pten/,
Tp53/ CD49fhi and PROM1+ cells. Data are re-
ported as mean % OFUs ± SEM.
(B) Immunohistochemistry (IHC) images ofWT and
Pten/,Tp53/ CD49fhi and PROM1+ organoids
stained for PTEN and quantification of PTEN+ or-
ganoids in each fraction. Data are reported as %
PTEN+ organoids ± SEM. Scale bars represent
100 mm.
(C) IHC images of pS6240/242 expression inWT and
Pten/,Tp53/ PROM1+ organoids. Scale bars
represent 50 mm.
(D) Representative IF (KRT5 and AR) and (KRT8
and TP63) images of G1 WT and Pten/,Tp53/
CD49fhi organoids.
*Multilineage organoid. Scale bars represent
50 mm. See also Figures S3 and S4.Tumor-Derived Organoids Are Observed in Both Basal
and Luminal Fractions
To begin evaluating the composition of primary tumors with
respect to their stem/progenitor phenotypes as well as clonal
tumor-initiating activity, we analyzed such properties in fraction-
ated populations of basal and luminal cells (Figure 1G). Using or-
ganoid culturing conditions that allow for in vitro growth of basal
and luminal stem/progenitor cells (Karthaus et al., 2014), we
compared the relative efficiencies of organoid formation from
the prostates of WT mice as well as PB-CRE4; Ptenfl/fl;Tp53fl/fl
and PB-CRE4; Ptenfl/fl tumor-bearing mice. Because there is a
continuum in morphologies from spherical to more complex
structures, we use the term ‘‘organoids’’ to signify clonal stem/
progenitor growth of >50 mm, regardless of morphology. WT
CD49fhi and PROM1+ fractions showed approximately 20%
and 2% organoid forming efficiency, respectively (Figure 2A),
consistent with other recently published reports describing rela-2150 Cell Reports 13, 2147–2158, December 15, 2015 ª2015 The Authorstively rare luminal fraction progenitors in
normal mice (Chua et al., 2014; Karthaus
et al., 2014). The organoid forming units
(OFUs) for the basal fraction of tumor-
bearing prostates was between 20%–
40%, demonstrating that the culture
conditions used here are highly efficient
in promoting clonal basal cell growth.
The CD49flo PROM1neg fraction rarely
formed organoids and was not further
analyzed. Notably, in comparing tumor
and WT luminal fractions, organoid for-
mation by the Pten/ Tp53/ fraction
was about 10-fold greater than wild-
type, while the Pten/ tumors demon-
strated relatively modest expansion of
luminal OFUs.
To determine the relative abundance
of WT (i.e., non-Pten deleted) progeni-
tors found in Pten/Tp53-null tumors, or-
ganoids derived from the basal andluminal progenitors from tumor-bearing and WT mice were
stained for PTEN expression. PTEN was expressed in nearly
100% of organoids from WT prostates (Figure 2B) but was
seen in %2% of either basal and luminal fraction of tumor-
derived organoids. Thus, at 14 weeks of age in PB-CRE4-
driven Pten/Tp53-deleted tumors, at which time the prostate
is usually significantly enlarged, the majority of cells that
grow in organoid cultures are tumor derived and rarely
contaminated with WT organoids. A lack of WT cells within
the tumor fractions was validated further by expression of
floxed Pten exon 5 in WT but not tumor organoids (Figure S3).
Further, to analyze pathways downstream of Pten deletion, we
stained sections of organoids for pS6240/242, a target down-
stream of RPS6KB1 and mTORC1 activation. Luminal-derived
organoids from WT prostates showed weak and patchy stain-
ing, while Pten/Tp53 organoids were stained uniformly strongly
(Figure 2C).
Figure 3. PROM1+ Progenitors Show
Heterogeneous Phenotypes in Organoid
Culture
(A) Representative phase images of first-genera-
tion translucent, acinar, and twined organoids
generated from PROM1+ cells. Organoid mor-
phologies are observed in wild-type (WT) and
Pten/,Tp53/ tumor fractions as indicated.
Scale bars represent 50 mm.
(B) Representative IF (KRT5 and AR) and (KRT8
and TP63) images of G1 WT and Pten/,Tp53/
PROM1+ organoids. The arrow indicates a luminal
WT organoid. Scale bars represent 50 mm.
(C) Representative phase, IF (KRT5 and KRT8 or
KRT5 and TP63), and IHC (pS6240/242) images of
G1 Pten/ PROM1+ multi-lobulated structures.
Scale bars represent 50 mm.
See also Figure S4.The CD49fhi fractions from WT and Pten/Tp53-null tumor-
derived prostates were characterized in organoid culture (Fig-
ure 2D). Histologically in tumors, basal cells were a minor
population occurring as scattered individual cells or within un-
common areas of adenosquamous carcinoma (Martin et al.,
2011). Organoids from the CD49fhi fractions were TP63+ with
KRT5+ peripheral cells and KRT8+ cells near lumen. Time-lapse
analyses of organoid development showed actively dividing
cells in the outer cortex of the CD49fhi tumor organoids (Fig-
ure S4; Movie S1). The tumor-derived organoids were
composed mostly of tightly packed concentric layers with small
lumen, which was an abundant phenotype observed in WT
prostate organoids as well. One clear difference between WT
and tumor organoids was easily observed AR staining in multi-
ple layers of WT organoids and a lack of AR staining in tumor
organoids (Figure 2D). In addition, the WT organoids notably
contained an infrequent (<10%) population characterized by
two to four cell layers around a large lumen, containing basal,
luminal, and AR+ cells (denoted by an asterisk in Figure 2D),
similar to the phenotype of ‘‘multilineage organoids’’ that
have recently been described (Karthaus et al., 2014). Taken
together, these data suggest that basal cells in the Pten/Tp53Cell Reports 13, 2147–2158, Demodel are predominantly a tumor-spe-
cific, committed basal phenotype.
Luminal Fraction Tumor-Derived
Organoids Demonstrate Luminal-
Only and Multilineage Phenotypes
The PROM1+ fraction from WT mice pro-
duced organoids that were heteroge-
neous in size and translucent with
discernable lumen (Figure 3A). Themajor-
ity of large organoids contained both
KRT8+/AR+ and KRT5+/TP63+ cells (Fig-
ure 3B), similar to the multilineage orga-
noids described previously, and confirm
multilineage organoids in both basal and
luminal fractions of WT prostate (Kar-
thaus et al., 2014). In addition, there wasa minor number of small, single-layered organoids (denoted by
arrow in Figure 3B) containing luminal cells with limited prolifer-
ative and self-renewing capacity, as these were no longer
observed upon serial passage (see Figure 4A).
PROM1+ Pten/Tp53-null tumor organoids were morphologi-
cally heterogeneous and notable for the presence of large, com-
plex twined structures, not usually observed in organoids
derived fromWT prostates (Figure 3A). Sections from fixed orga-
noids as well as time-lapse microscopy suggested that a contin-
uously enlarging central lumen twisted and folded back upon
itself to produce twined single lumen-containing structures (Fig-
ure S4; Movie S2). Histological analyses revealed two types of
organoids: multilineage and luminal only. The multilineage orga-
noids usually displayed a twined structure, suggesting a hyper-
proliferative phenotype relative to WT multilineage organoids.
Interestingly, large luminal-only organoids were not observed
in WT prostates suggesting a tumor-specific characteristic. Tu-
mor-specific luminal-only organoids have not been specifically
described previously in mouse models of prostate cancer,
although luminal organoids have been derived from clinical met-
astatic adenocarcinoma prostate cancer biopsies (Gao et al.,
2014). Luminal-only organoids predominated in frequency atcember 15, 2015 ª2015 The Authors 2151
Figure 4. Differentiation Potential of Multili-
neage and Luminal Organoids In Vitro and
In Vivo
(A) Representative phase images of G1 organoids
isolated from WT and Pten/,Tp53/ PROM1+
cells and IF (KRT5+KRT8) confocal images of
daughter organoids generated from the cloned
organoids. Scale bars represent 100 mm. Note that
there are relative differences in magnification for
the panels shown.
(B) Representative H&E, IHC (TP63 and AR), and IF
(KRT5 and KRT8) images of regions of ad-
enosquamous (left) and adenocarcinoma (right) in
tumors generated from G1 PROM1+ organoids.
The black arrow indicates nuclear TP63 labeling of
cells situated along the basement membrane
adjacent to an adenocarcinoma gland. Scale bars
represent 50 mm.16–18 weeks of age, and the relative proportion varied between
about 60% and 90% in individual tumors. The levels of AR
expression in PROM1+ Pten/Tp53-null organoids were generally
lower than WT organoids, consistent with relatively low levels of
AR in Pten/Tp53-null tumors (Figure 3B).
Luminal Progenitor Phenotypes Are Enriched in Pten/
Tp53 Co-deleted Tumors Relative to Pten-Null-Only
Tumors
Because PB-CRE4;Ptenfl/fl;Tp53fl/fl and PB-CRE4;Ptenfl/fl pros-
tates demonstrated distinct distributions of organoids relative
to the basal and luminal fractions (Figure 2A) as well as previ-
ously characterized differences in prostate cancer pathogenesis
(Chen et al., 2005; Martin et al., 2011; Wang et al., 2006), we per-
formed histological analyses on organoids from age-matched
(16–18 weeks) prostates for comparison. As anticipated, the
Pten-null luminal fraction contained relatively few (<10%) luminal
(KRT8+/TP63neg) organoids >50 mm, consistent with total orga-
noid plating efficiency (Figure 2A). Pten-null-only prostates con-
tained large, solid lobulated structures present in both luminal
and basal fractions, which displayed high pS6240/242 staining
(Figure 3C). Lobules were organized with KRT5+/TP63+/AR+
cells on the periphery and KRT8+ cells near the centers, demon-
strating histological and morphological characteristics distinct
from Pten/Tp53-null stem/progenitor cells and consistent with
deregulated growth of basal multipotent progenitors. These
data imply that the loss of Tp53 in the context of Pten deletion
specifically supports survival or amplification of luminal-
committed progenitors. Our findings are consistent with the
described expansion of basal stem/progenitor cells in PB-CRE4;
Ptenfl/fl prostates (Wang et al., 2006) and with the significantly
more rapid development of adenocarcinoma in PB-CRE4;
Ptenfl/fl;Tp53fl/fl compared to PB-CRE4;Ptenfl/fl prostates (Chen
et al., 2005; Martin et al., 2011).2152 Cell Reports 13, 2147–2158, December 15, 2015 ª2015 The AuthorsMultilineage and Luminal
Progenitors Are Serial Stages in
Luminal Commitment
Serial passage of Pten/Tp53-null
PROM1+ organoids demonstrated con-tinued presence of both multilineage and luminal phenotypes.
In order to analyze the self-renewal and differentiation properties
of the progenitors giving rise to the two organoid phenotypes, in-
dividual organoids were clonally isolated from G1 organoid
populations, serially passaged as a single-cell suspension and
subsequently analyzed histologically at G2 or G4 for organoid
phenotype (Figure 4A). Individual, tumor-derived organoids
passaged at nearly 100% efficiency and were observed for a
minimum of six passages. Two types of differentiation patterns
were observed from individual tumor organoids: one pattern
showed a mixture of multilineage and luminal phenotyped orga-
noids, and the other pattern showed luminal phenotyped orga-
noids only. The former pattern generally correlated with large,
twined organoids and the latter with acinar organoids. No cul-
tures contained only multilineage organoids. These data strongly
imply that multipotent tumor progenitors produce multilineage
and luminal organoids, while luminal-committed tumor organo-
ids renew themselves and maintain a luminal phenotype.
Similar analyses carried out with individual WT PROM1+ orga-
noids showed that large organoids could be efficiently passaged
for at least six generations and gave rise to a combination of mul-
tilineage and basal organoid phenotypes (Figure 4A), in contrast
to multilineage and luminal phenotypes derived from multiline-
age tumor organoids. These data suggest that Pten/Tp53 loss
in multipotent progenitors may increase luminal and decrease
basal commitment or survival of daughter progenitors. In addi-
tion, we were unable to serially propagate WT luminal-only orga-
noids, unlike tumor-derived luminal organoids.
PROM1+ Tumor Organoids Display Luminal and
Bipotential Differentiation In Vivo
To investigate the tumorigenicity and resulting histopathology of
organoids, we performed subcutaneous injection of single-cell
suspensions derived from G1 tumor organoids. WT organoids
Table 1. Tumor-Propagating Cell Frequency in Each Population
Was Determined by Limiting Dilution Analysis using L-Calc
Software with the Transplanted Cell Numbers Shown
CD49fhi PROM1+
Tumor histology
Adenocarcinoma n = 2 n = 4
Adenosquamous n = 1 n = 2
No. Cells/Injection No. Mice with Tumors/No. Mice Transplanted
100–1,200 0/6 0/4
1,200–10,000 1/8 3/8
10,000–50,000 1/7 0/3
50,000–100,000 1/1 3/8
>100,000 0/0 0/0
3/22 6/23
Frequency of TPC 1/98,060 1/103,032
0.4724
Pooled fractions obtained from two to four tumor-bearing animals were
used in each experiment. The number of independent experiments was
nine CD49hi and eight PROM1+. Summary of histological phenotypes of
primary transplant tumors is shown.did not grow under these conditions. PROM1+G1 tumor organo-
ids produced tumors, which contained multiple foci displaying
one of two possible phenotypes, embedded in stroma and disor-
ganized tumor cells. One type of focus consisted of irregular,
mostly small, adenocarcinoma glands suggesting initiation
from a luminal-committed progenitor (Figure 4B, right panels).
These glands were composed of KRT8+/KRT5neg/AR+ cells
with no TP63+ cells within or adjacent to the glands. The other
type of focus demonstrated a consistent adenosquamous histol-
ogy indicating bipotent lineage differentiation (Figure 4B, left
panels). Adenosquamous transformed foci were composed of
variably sized glandular structures lined with a layer of luminal
cells that often transitioned into an area of disorganized piling
at the edge of the lumen with continuation into an adjacent
area of squamous differentiation. This histology clearly forms a
continuum in lineage transition (Figure S5) and is pathologically
distinct from the pattern anticipated for tumors initiated from
two or more lineage-committed cells. In addition, squamous his-
tology alone was never observed, providing evidence that
tumorigenic basal-committed stem/progenitor cells are exceed-
ingly rare or absent. TP63 staining was strong in the squamous
histology and contained in intermittent basilar located cells adja-
cent to the luminal glandular regions (denoted by an arrow, Fig-
ure 4B). A high proportion of cells within adenocarcinoma and
squamous histological phenotypes were nuclear AR+. These
data show that the foci observed in vivo parallel the lineage
composition of multilineage (adenosquamous) and luminal
(adenocarcinoma) organoids.
By contrast, tumor-derived, CD49fhi organoids from several
independent cultures did not produce detectable tumor growth
after in vivo transplantation. We hypothesize that the majority
of Pten/Tp53-null CD49fhi cells are committed basal cells,
consistent with the organoid morphologies shown in Figures
2B and 2D. Such cells proliferate well in organoid culture condi-
tions (Figure 2A), but basal cells have been shown in models ofCell Repbasal keratin CRE-driven Pten/Tp53 deletion to be relatively
resistant to oncogenic growth (Choi et al., 2012).
Luminal and Basal TICs Demonstrate Luminal-
Committed and Multilineage Tumor-Initiating Activity
Next, we analyzed the tumor-initiating activity of CD49fhi and
PROM1+ fractions isolated directly fromprimary tumors. Limiting
dilution analysis was performed using subcutaneous injection of
cells with Matrigel into NOD/SCIDmice in the absence of embry-
onic urogenital mesenchyme (UGM) in order to evaluate autono-
mous tumorigenic and lineage differentiation activity without
exogenous differentiating signals. Cell numbers used for limiting
dilution injections ranged from 100 to 100,000 cells per injection
(Table 1). For the PROM1+ fraction, tumor formation was rela-
tively uncommon, reflecting an autonomous tumor-initiating
cell frequency of 1/100,000. Importantly, two independent tu-
mor histologies were observed: adenosquamous carcinoma
and adenocarcinoma with variable amounts of sarcomatoid car-
cinoma, consistent with histologies found in primary GEM tu-
mors (Martin et al., 2011). Squamous-only tumors were not
observed. Epithelial mesenchymal transition (EMT) trans-differ-
entiation of EpCAM+ Pten/Tp53-null adenocarcinoma to sarco-
matoid morphology occurs in Pten/Tp53-null tumors and has
been previously characterized (Liu et al., 2012; Martin et al.,
2011).
Adenocarcinoma was KRT8+/TP63neg/KRT5rare with glands
demonstrating a high frequency of AR+ cells (Figure 5, right
panels). For the adenosquamous tumors, there was clear conti-
nuity between adenocarcinoma and squamous histological phe-
notypes, showing a common origin (Figure 5, left panels). Both
adenocarcinoma and basal components were AR+. The glan-
dular component was composed of KRT8+/TP63neg cells with
intermittent TP63+ cells in a basal position, while the squamous
tumor cells were strongly KRT5+/TP63+. These data imply that a
multipotent stem cell produced prostatic acini organized with
basal and luminal components as well as areas of committed
basal cell (squamous) tumors. In addition, we observed in one
clonally initiated adenosquamous tumor from the PROM1+
fraction that serial passage of the initial tumor gave rise to adeno-
carcinoma tumors in three recipients, demonstrating that
luminal-committed TICs can arise from adenosquamous tumors,
consistent with the lineages produced by serially passaged indi-
vidual, mutilineage organoids (summarized in Figure 5B).
Tumor-initiating cell assays were performed with the CD49fhi
fraction. We observed tumor initiation leading to adenocarci-
noma and adenosquamous histological phenotypes at a fre-
quency of 1/100,000 (Table 1). The existence of cells with
tumorigenic potential in the basal fraction is consistent with pre-
vious analyses demonstrating tumor initiation by bulk popula-
tions of PB-CRE4 Ptenfl/fl basal cells (Mulholland et al., 2009).
The presence of TICs contrasts with the lack of tumorigenicity
for organoids derived from the CD49fhi fraction. Although various
explanations are possible, we favor the interpretation that
endogenous CD49fhi TICs in this model are relatively rare
compared to non-tumorigenic Pten/Tp53-deleted basal cells,
and therefore are not routinely recovered in organoid cultures.
This would seem inconsistent with a similar TIC frequency be-
tween basal and luminal fractions. However, because the relativeorts 13, 2147–2158, December 15, 2015 ª2015 The Authors 2153
Figure 5. PROM1+ Cells Demonstrate Luminal-Committed and Multilineage Tumor-Initiating Activity In Vivo
(A) Representative H&E, IHC (AR), and IF (KRT5 and KRT8 or KRT5 and TP63) staining of regions of adenosquamous (left panels) or adenocarcinoma (right panels)
from tumors initiated from Pten/,Tp53/ PROM1+ cells. White arrows indicate nuclear TP63 staining in adenosquamous tumors. TP63 staining was not
observed in adenocarcinoma. Ad, adenocarcinoma region; Sq, squamous carcinoma. Scale bars represent 50 mm.
(B) Schematic representation of clonally initiated in vitro progenitor activity and tumor phenotypes originating from luminal and basal fractions of Pten/Tp53/
tumors.
See also Figure S5.efficiencies of tumor initiation by luminal as compared to basal
cells under the conditions used here are not known, direct quan-
titative comparisons between the two fractions cannot be made.
To summarize (Figure 5B), there are multiple autonomous
TICs in primary prostate tumors, included within both the
CD49fhi basal and the PROM1+ luminal fractions that give rise
to either adenosquamous or adenocarcinoma. These data,
based upon analyses of organoid phenotypes and tumorige-
nicity as well as clonal TIC phenotypes in vivo, strongly support
the existence of transformedmultipotent and luminal-committed
progenitors resulting from PB-CRE4-initiated deletion of Pten
and Tp53. Importantly, the existence of multipotent TICs implies
that multilineage organoids reflect endogenous progenitors
and are not solely a conditional phenotype induced by ex vivo
culture.
A Fraction of PROM1+ Stem/Progenitor Cells Are
Castration Tolerant
A central question in prostate cancer biology is the cellular ori-
gins of castration resistance. To begin addressing this question,
we have evaluated the in vivo castration sensitivity or tolerance
(survival) of progenitors giving rise to organoids The histopathol-2154 Cell Reports 13, 2147–2158, December 15, 2015 ª2015 The Auogy of castration in 14- to 16-week-old Pten/Tp53-null tumors
was analyzed between 3 days and 6 weeks. Histologically,
androgen deprivation led to attenuation in the size of tumor cells,
increased vacuolation of luminal-appearing cells, and a subpop-
ulation of cells with increased cytoplasmic basophilia/anaplasia,
especially in the ventral prostate. Apoptosis, assayed by nuclear
cleaved CASP3, was increased at day 3 and reached plateau
levels by day 12, which were maintained for several weeks (Fig-
ure S6A). Nuclear AR localization was used as a measure of AR
activity in tissue sections (Figure 6A). Following castration, AR
staining mostly was diffuse and cytoplasmic, but, by 7 days
post-castration, clusters of cells with weak nuclear AR staining
and representing less than 10% of total tumor cells were
observed in all prostate lobes. Two weeks was chosen as a
short-term castration time point to assay the in situ tolerance
of stem/progenitor populations for androgen deprivation. Due
to the stoichastic potential of this model for sarcomatoid trans-
formation, long time points were not feasible.
FACS analysis of tumors from mice castrated 2 weeks earlier
demonstrated CD49fhi, PROM1+, and CD49flo PROM1neg frac-
tions in approximately similar proportions to intact tumors
(Figure S6B). RT-PCR analyses of the fractions obtained fromthors
Figure 6. A Fraction of PROM1+ Stem/Progenitor Cells Are Castra-
tion Tolerant
(A) IHC images of AR staining of Pten/,Tp53/ prostate tissue from intact
animals or 7 days post-castration. Scale bars represent 50 mm.
(B) Histological comparison of PROM1+organoids generated from intact and
castrated Pten/,Tp53/ prostate.
(C) Representative IHC AR staining of PROM1+ organoids generated from
castrated Pten/,Tp53/ prostate. Scale bars represent 50 mm.
(D) Representative IHC AR staining in tumors generated from castrate
Pten/,Tp53/ G1 PROM1+ organoids. Inset a shows invasive cells; inset b
shows nuclear atypia. Scale bars represent 50 mm.
(E) Histological comparison of PROM1+organoids generated from non-cas-
trated Pten/,Tp53/ prostate following enzalutamide treatment and growth
for 7 days.
**p% 0.01, *p% 0.05. See also Figure S6.castrate as compared to intact tumors revealed population-spe-
cific transcription responses (Figure S6C) such as increased
levels of Tp63,Krt5, andKrt18 in the basal fraction and increased
Clu in the luminal fraction. Clu expression previously has
been described as a luminal progenitor marker in PSA-CRE;
Ptenflox/flox mice (Korsten et al., 2009).
Castrated tumor fractions were characterized for the growth
and differentiation potential of surviving progenitors in organoid
cultures. The CD49fhi fraction showed no significant changes inCell RepOFUs (Figure S6D) and no obvious morphological/lineage
changes following castration, consistent with undetectable AR
expression in most tumor-derived basal organoids (Figure 2D).
Histological analyses of harvested PROM1+ fraction organoids
demonstrated that both multilineage and luminal organoids
were reduced following castration (Figure 6B). Because multipo-
tent progenitors can give rise to luminal progenitors, the inhibi-
tion or loss of multipotent progenitors in vivo following castration
may be reflected in in vitro numbers of both multilineage and
luminal organoids. Interestingly, the PROM1+ organoids initiated
from castrated tumors contained a high percentage of nuclear
AR+ cells in the presence of dihydrotestosterone (DHT), showing
that castrate-tolerant luminal cells retained the potential for
AR signaling (Figure 6C). Consistent with this, transplantation
of cell suspensions of PROM1+ G1 organoids derived from
castrated tumors resulted in tumor foci with glandular morphol-
ogies (KRT8+/AR+/TP63rare) embedded in stroma (Figure 6D).
Neoplastic epithelial cells formed both low-grade mPIN lesions
as well as invasive adenocarcinoma (inset a). Neoplastic cells
had expected features of nuclear atypia including a euchromatin
pattern and one to two prominent nucleoli (inset b). Therefore, a
fraction of luminal progenitor cells appeared to be castration
tolerant, some of which were capable of autonomously produc-
ing AR+ adenocarcinoma in vivo.
To compare castration to autonomous AR inhibition, we
added 10 mM enzalutamide in the absence of DHT at the time
of organoid initiation from the luminal fraction of intact (non-cas-
trated) tumors (Figure 6E). Enzalutamide noticeably slowed but
did not prevent the growth of PROM1+ organoids. Histological
analyses showed a statistically significant decrease in numbers
of multilineage organoids and a smaller, statistically insignificant
decrease in luminal organoids. Overall, enzalutamide treatment
confirms the AR-dependence of organoid initiation by a fraction
of Pten/Tp53-null multilineage progenitors but also revealed the
resistance to AR inhibition of a significant population of progen-
itors in the luminal fraction.
DISCUSSION
This study characterizes primary prostate tumors initiated by
loss of the common tumor suppressors, Pten and Tp53, for
stem/progenitor phenotypes as assayed by in vitro organoid cul-
tures and in vivo tumor-initiating activity. It has not been routinely
possible to culture luminal stem/progenitor cells, which has pre-
vented ex vivo analysis of these important cells in primary pros-
tate tumors, biasing most studies toward primary basal cells or
human prostate cancer cell lines (Wang and Shen, 2011). We
have observed two classes of self-renewing luminal progenitors
in Pten/Tp53-null tumors, a minor population giving rise to
multilineage organoids (multipotent progenitors) and a major
population producing luminal-only organoids (luminal committed
progenitors) (Figure 5B). Of particular interest is the observation
that multilineage organoids give rise to self-renewing luminal or-
ganoids, providing additional insight into progenitor subpopula-
tions, lineage stages leading to luminal commitment, and one
route of prostate adenocarcinoma histogenesis. We suggest
that combined loss of Pten and Tp53 either in the luminal
multipotent progenitor or a precursor has revealed a naturallyorts 13, 2147–2158, December 15, 2015 ª2015 The Authors 2155
transient population, possibly by inhibiting the normal rate of dif-
ferentiation. This interpretation is consistent with considerable
evidence linking Tp53 to the regulation of differentiation in
stem cells (Bonizzi et al., 2012; Cicalese et al., 2009).
To date, luminal multipotent progenitor cells have not been
observed in lineage tracingexperiments (Choi et al., 2012;Ousset
et al., 2012;Wang et al., 2013), except in the case of rare CARN’s
(Wanget al., 2009), promptingquestions about thesignificanceof
the multipotent progenitors revealed in organoid cultures. We
show the existence of multipotent and luminal-committed TICs
isolated directly from tumors, producing either adenosquamous
carcinoma or adenocarcinoma, respectively. Importantly, the
TIC assays used here measured autonomous differentiation
potential in the absence of inductive embryonic urogenital
mesenchyme (Neubauer et al., 1983; Taylor et al., 2009). Endog-
enous adenosquamous prostate carcinoma is observed in a
fraction of PB-CRE4; Ptenfl/fl;Tp53fl/fl mice (Martin et al., 2011),
supporting the concept that transformedmultipotent progenitors
exist in vivo and can differentiate to both basal and luminal
lineages in tumors in situ. It seems likely that the microenviron-
ment will influence lineage commitment, and we note that orga-
noids and TIC assays are performed in the absence of stromal
cells. Therefore, it is possible in these assays that the extent of
basal cell commitment by multilineage progenitors may be
increased relative to the endogenous microenvironment.
Although engineeredmodels of prostate cancer are often used
to analyze the consequences of combined genetic mutations
(Shen and Abate-Shen, 2010), the effect upon stem/progenitor
populations has not been commonly considered. We show
here for PB-CRE4-initiated genetic changes that Tp53 in combi-
nation with Pten loss demonstrated significantly different stem/
progenitor populations compared to Pten loss alone. Specif-
ically, Tp53 loss leads to the presence of luminal multipotent
stem/progenitor cells and a self-renewing luminal population,
correlated with accelerated adenocarcinoma development, that
is absent in Pten-null prostates. In addition, it is possible that
Tp53 loss primes for lineage plasticity, similarly to the phenotypic
dedifferentiation of luminal mammary epithelium following Brca1
loss (Molyneux et al., 2010). Analyses of stem/progenitor popula-
tions contribute fundamental knowledge for molecular and path-
ological comparisons of GEM models and for interpretation of
target populations responding to therapeutics, as exemplified
for castration/enzalutamide sensitivity in Figure 6.
Due to a lack of biomarkers, the extent of innate stem/progen-
itor subpopulation heterogeneity in human prostate cancer is not
known. However, histological heterogeneity is common in cas-
trate-resistant metastatic prostate cancer (Roudier et al., 2003;
Shah et al., 2004), suggesting expression of ‘‘stemness’’ proper-
ties through pre-existing or acquired mechanisms. With respect
to the multipotent progenitor described here, the existence of
prostate adenosquamous carcinoma in humans is exceedingly
rare (Giannico et al., 2013; Humphrey, 2012). However, the tem-
poral accumulation of mutations in human prostate cancer or the
microenvironment may favor luminal differentiation by multipo-
tent progenitors. It remains to be determined whether a luminal
multipotent stem/progenitor cell may be a cell of origin or similar
to a cancer stem cell population in human prostate cancer.
Another population described here, castration-tolerant luminal2156 Cell Reports 13, 2147–2158, December 15, 2015 ª2015 The Auprogenitor cells, are candidates as potential cellular targets for
the accumulation of acquired resistance mutations in response
to androgen deprivation therapies (Goldstein et al., 2010). Simi-
larly, castration-tolerant luminal cells have been observed in pri-
mary human prostate cancer xenografts (Toivanen et al., 2013).
The ability to isolate and assay-specific stem/progenitor popula-
tions frommice is an important resource for future investigations
into molecular and proteomic markers that uniquely distinguish
various stem/progenitor cell populations, which will enable
refined lineage tracing approaches and histopathological ana-
lyses of clinical samples.
EXPERIMENTAL PROCEDURES
Isolation, Labeling, and FACS Sorting of Primary Prostate Epithelial
Cells
Single-cell suspensions of WT and Pten/,Tp53/ prostate tissue were pre-
pared as previously described (Abou-Kheir et al., 2010). For labeling reactions,
cells were resuspended in PBS (without Mg2+ or Ca2+) containing 1% heat-in-
activated fetal bovine serum (FBS). All antibodies and reagents were pur-
chased from BD Pharmingen unless otherwise stated. Fcg III/II receptors
were blocked using anti-CD16/CD32 antibody for 15 min at 4C. Cells were
stained with CD45-FITC, CD31-FITC, Ter-119-FITC, EpCAM-APC-Cy7
(BioLegend), CD49f-PE, and Prominin-1-APC (Miltenyi Biotech) for 30 min at
4C. 7-Aminoactinomycin D (Sigma) 100 mg ml–1 was added prior to analysis.
Cell sorting was performed on FACSVantage and FACSAria cell sorters
(Becton Dickinson) using FACSDiva software. The FACS gating strategy for
CD49f/PROM1 fractionation is shown in (Figure S2A).
Organoid Culture, Passage, and Clone Isolation
Single-cell suspensions were cultured in organoid culture conditions, consist-
ing of embedding cells within a Matrigel matrix and incubating with modified
ENR media as described in Karthaus et al. (2014), except that Matrigel-con-
taining cells was spread in a thin ring around the circumference of a six-well
plate instead of as a drop. For passage, organoids were harvested and pro-
cessed to single cells as described (Abou-Kheir et al., 2010) prior to being re-
plated. For isolation of clonal organoids, 1,000 PROM1+ cells were seeded on
top of aMatrigel-coatedwell of a six-well plate. Cells were allowed to attach for
30 min at 37 degrees. Subsequently, cells were covered with 1 ml of media
containing 5% Matrigel. After 6–7 days, organoids were individually isolated
under the microscope, deposited into a single well of a 96-well plate, visually
checked for purity, and then trypsinized (0.05%) and seeded as single cells
embedded within Matrigel into a 12-well plate. Organoids were then passaged
over several generations at least through G6.
Generation of PB-Cre4, Pten–/–,Tp53–/– Mice
All animal care was provided in accordance with the procedures outlined by
the National Cancer Institute Guideline for the Care and Use of Laboratory An-
imals. PB-Cre4,Pten–/–,Tp53–/– mice were generated as previously described
(Martin et al., 2011). Male NOD/SCID mice (4–6 weeks old) were obtained
from the NCI Frederick-Animal Production Program.
Additional methods are included in the Supplemental Experimental
Procedures.
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